Decades of leadership in Oncology with a diverse and robust pipeline
Overview of scientific approaches fueling our early-stage pipeline.
Information on ongoing and past clinical trials
We aspire to cure cancer with inspiration from patients and innovation from everywhere
We are committed to helping people with cancer navigate every part of their journey
We believe the best way to achieve our aspiration to cure cancer is by working together
In recent years, we’ve seen remarkable progress in combatting devastating cancers, with the rise of immunotherapies across a breadth of therapeutic modalities, from antibody-based immunomodulators to cell-based therapies to other emerging technologies. And yet, while there are more than 30 approved immunotherapies on the market today, only about 15-20% of patients respond to available treatments, demonstrating a necessity for more effective and tolerable options.
